TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00365859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
Study: NCT02380066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anyu Peibo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anyu Peibo
Description: Placebo
Study: NCT00365859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
Study: NCT03708744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: M207 3.8 mg, 30 min, thigh
Description: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B: M207 3.8 mg, 30 min, thigh
Description: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: M207 3.8 mg, 1 hr, upper arm
Description: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: M207 3.8 mg, 1 hr, upper arm
Description: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: M207 3.8 mg, 1 hr, upper arm
Description: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
Study: NCT02232529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05582863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise intervention
Description: The experimental group performed a 75-90-minute VR exercise routine twice a week for 12 weeks.
Study: NCT00406029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 1 mg BID capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 2 mg BID capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 5 mg BID capsules
Study: NCT03708744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C: M207 3.8 mg, 1 hr, upper arm
Description: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D:zolmitriptan nasal spray
Description: D: 2.5 mg/0.1 mL intranasal zolmitriptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D:zolmitriptan nasal spray
Description: D: 2.5 mg/0.1 mL intranasal zolmitriptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D:zolmitriptan nasal spray
Description: D: 2.5 mg/0.1 mL intranasal zolmitriptan
Study: NCT00406029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 10 mg BID capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-dopa
Description: Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
Study: NCT04592198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride Buccal Film 0.25 Mg
Description: Dose equal to the iv control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride Buccal Film 0.5 Mg
Description: Dose twice that of iv control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
Description: iv control
Study: NCT00667498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia.
Study: NCT00406029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Other Parkinson's Disease treatments
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Parkinson's Disease treatments
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
Study: NCT00667498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia.
Study: NCT00730470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287 (AMG888)
Description: IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
Study: NCT03708744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D:zolmitriptan nasal spray
Description: D: 2.5 mg/0.1 mL intranasal zolmitriptan
Study: NCT03805698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma (PRP)
Description: The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arthroscopic Debridement
Description: Standard arthroscopic debridement. No PRP injection.
Study: NCT01000415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by surgery
Description: Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
Study: NCT02765347

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: For arm 2, just accept insulin for 24 weeks
Study: NCT01400217

Intervention type: DRUG
Intervention: extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
Description: IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
Study: NCT03896919

Intervention type: DIAGNOSTIC_TEST
Intervention: HLA-DQ by luminex technology in kidney transplantation
Description: HLA typing (DQ) for donor and recipient using Luminex microbead method from EDTA blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: HLA-DQ by luminex technology in kidney transplantation
Description: HLA typing (DQ) for donor and recipient using Luminex microbead method from EDTA blood sample
Study: NCT01409018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: pharmacokinetics
Study: NCT03151993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase
Description: 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
Study: NCT00031837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalteparin
Study: NCT00406029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Parkinson's Disease treatments
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Parkinson's Disease treatments
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
Study: NCT00406029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Parkinson's Disease treatments
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
Study: NCT04408469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online EQuIP
Description: This online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-monitoring control
Description: Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
Study: NCT01400217

Intervention type: DRUG
Intervention: extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
Description: IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug

Intervention type: DRUG
Intervention: extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
Description: IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug

Intervention type: DRUG
Intervention: standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
Description: IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug

Intervention type: DRUG
Intervention: standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
Description: IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug

Intervention type: DRUG
Intervention: standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
Description: IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
Study: NCT02342275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
Study: NCT00120393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
Description: Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/r +2 NRTIs (Delayed/optional Switch Group)
Description: Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
Study: NCT03788486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-3 Joule LED blue light device
Description: application of blue light LED light device for 2 minutes in the central lower lids, temporal lower lids and upper temporal lids twice weekly under observation for one month
Study: NCT00031837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT02665611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention for improvement of adherence
Description: intervention for improvement of adherence
Study: NCT00244738

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Castor oil
Description: Patients who received castor oil for labor induction

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil
Description: Patients who received sunflower oil as a placebo
Study: NCT02665611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treatment as usual
Description: The control group will be treated according to the usual stadard of care.
Study: NCT03088384

Intervention type: DRUG
Intervention: Ketamine
Description: Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
Study: NCT02342275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
Study: NCT02100189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo esophageal cytology collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo standard EGD or endoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02721420

Intervention type: DRUG
Group type: OTHER
Intervention: dihydroartemisinin-piperaquine

Intervention type: DRUG
Group type: OTHER
Intervention: dihydroartemisinin-piperaquine

Intervention type: DRUG
Group type: OTHER
Intervention: dihydroartemisinin-piperaquine

Intervention type: DRUG
Group type: OTHER
Intervention: dihydroartemisinin-piperaquine

Intervention type: DRUG
Group type: OTHER
Intervention: dihydroartemisinin-piperaquine

Intervention type: OTHER
Group type: OTHER
Intervention: message(SMS) reminder

Intervention type: OTHER
Group type: OTHER
Intervention: Health worker reminder
Description: Health surveillance assistants reminders prior to each treatment course

Intervention type: OTHER
Group type: OTHER
Intervention: short message(SMS) reminder
Study: NCT02137928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin periocular injection
Description: 20mg/2ml carboplatin periocular injection together with chemotherapy
Study: NCT02460991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB-TACE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Study: NCT00273611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Education about Vitamin D
Study: NCT04183933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Exercise
Description: Pilates exercises will be given for 6 weeks, 3 days in a week.
Study: NCT02137928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
Study: NCT00360971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: palifermin
Description: Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
Study: NCT04183933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Exercise
Description: Combined exercise will be given for 6 weeks, 3 days in a week.
Study: NCT01224262

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
Description: A single vaccination of Fluzone alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
Description: A single vaccination of Fluzone alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
Description: A single vaccination of Fluzone alone
Study: NCT00360971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
Study: NCT01224262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIQ001 (0.45mg)
Description: A single vaccination of 0.45 mg LIQ001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIQ001 (1.8mg)
Description: A single vaccination of 1.8 mg LIQ001
Study: NCT02358577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-bed cycling
Description: In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
Study: NCT04020510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onaBoNT-A
Description: Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onaBoNT-A
Description: Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
Study: NCT02546544

Intervention type: DRUG
Group type: OTHER
Intervention: Linsitinib
Study: NCT00863850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled \[14C\] bendamustine will be given on day 1 of cycle 1 only.
Study: NCT02810535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE
Study: NCT00434057

Intervention type: DEVICE
Group type: OTHER
Intervention: MelaFind(R)
Description: Biopsy ratio comparison